Theratechnologies Inc. (THTX)

Overview News Price History Option Chain Why THTX Down? Discussions Forecast Stock Split

Theratechnologies Inc. stock is currently priced at $1.34, with a 24-hour trading volume of 6,695. It has seen a -1.47% decreased in the last 24 hours and a +5.51% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.34 pivot point. If it approaches the $1.32 support level, significant changes may occur.

Theratechnologies Inc. Stock (THTX) Financials Data

Theratechnologies Inc. (THTX) Revenue 2024

THTX reported a revenue (TTM) of $81.76 million for the quarter ending November 30, 2023, a +2.13% rise year-over-year.

Theratechnologies Inc. (THTX) Net Income 2024

THTX net income (TTM) was -$23.96 million for the quarter ending November 30, 2023, a +49.28% increase year-over-year.

Theratechnologies Inc. (THTX) Cash Flow 2024

THTX recorded a free cash flow (TTM) of -$7.50 million for the quarter ending November 30, 2023, a +52.18% increase year-over-year.

Theratechnologies Inc. (THTX) Earnings per Share 2024

THTX earnings per share (TTM) was -$0.90 for the quarter ending November 30, 2023, a +54.31% growth year-over-year.

Theratechnologies Inc. Stock (THTX) Latest News

Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders

GlobeNewswire Inc.

Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire Inc.

Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024

GlobeNewswire Inc.

Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform

GlobeNewswire Inc.

Theratechnologies Appoints Elina Tea to its Board of Directors

GlobeNewswire Inc.

Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update

GlobeNewswire Inc.

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.